Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;62(2):322-334.
doi: 10.1007/s00125-018-4770-4. Epub 2018 Nov 15.

Therapeutic Regulation of VE-cadherin With a Novel Oligonucleotide Drug for Diabetic Eye Complications Using Retinopathy Mouse Models

Affiliations

Therapeutic Regulation of VE-cadherin With a Novel Oligonucleotide Drug for Diabetic Eye Complications Using Retinopathy Mouse Models

Ka Ka Ting et al. Diabetologia. .

Abstract

Aims/hypothesis: A major feature of diabetic retinopathy is breakdown of the blood-retinal barrier, resulting in macular oedema. We have developed a novel oligonucleotide-based drug, CD5-2, that specifically increases expression of the key junctional protein involved in barrier integrity in endothelial cells, vascular-endothelial-specific cadherin (VE-cadherin). CD5-2 prevents the mRNA silencing by the pro-angiogenic microRNA, miR-27a. CD5-2 was evaluated in animal models of ocular neovascularisation and vascular leak to determine its potential efficacy for diabetic retinopathy.

Methods: CD5-2 was tested in three mouse models of retinal dysfunction: conditional Müller cell depletion, streptozotocin-induced diabetes and oxygen-induced retinopathy. Vascular permeability in the Müller cell-knockout model was assessed by fluorescein angiography. The Evans Blue leakage method was used to determine vascular permeability in streptozotocin- and oxygen-induced retinopathy models. The effects of CD5-2 on retinal neovascularisation, inter-endothelial junctions and pericyte coverage in streptozotocin- and oxygen-induced retinopathy models were determined by staining for isolectin-B4, VE-cadherin and neural/glial antigen 2 (NG2). Blockmir CD5-2 localisation in diseased retina was determined using fluorescent in situ hybridisation. The effects of CD5-2 on VE-cadherin expression and in diabetic retinopathy-associated pathways, such as the transforming growth factor beta (TGF-β) and wingless/integrated (WNT) pathway, were confirmed using western blot of lysates from HUVECs, a mouse brain endothelial cell line and a VE-cadherin null mouse endothelial cell line.

Results: CD5-2 penetrated the vasculature of the eye in the oxygen-induced retinopathy model. Treatment of diseased mice with CD5-2 resulted in reduced vascular leak in all three animal models, enhanced expression of VE-cadherin in the microvessels of the eye and improved pericyte coverage of the retinal vasculature in streptozotocin-induced diabetic models and oxygen-induced retinopathy models. Further, CD5-2 reduced the activation of retinal microglial cells in the streptozotocin-induced diabetic model. The positive effects of CD5-2 seen in vivo were further confirmed in vitro by increased protein expression of VE-cadherin, SMAD2/3 activity, and platelet-derived growth factor B (PDGF-B).

Conclusions/interpretation: CD5-2 has therapeutic potential for individuals with vascular-leak-associated retinal diseases based on its ease of delivery and its ability to reverse vascular dysfunction and inflammatory aspects in three animal models of retinopathy.

Keywords: Blood–retinal barrier; Diabetic retinopathy; MicroRNA; Microglia; Müller cells; Neovascularisation; Oligonucleotide; Pericytes; VE-cadherin.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Diabetes. 2002 Oct;51(10):3107-12 - PubMed

References

    1. Diabetes. 2005 May;54(5):1559-65 - PubMed

References

    1. Graefes Arch Clin Exp Ophthalmol. 2009 Sep;247(9):1205-11 - PubMed

References

    1. Diabetes. 2009 Jul;58(7):1659-67 - PubMed

References

    1. Am J Ophthalmol. 2000 Feb;129(2):267-9 - PubMed

References

    1. Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5240-6 - PubMed

References

    1. Sci Rep. 2016 Jul 06;6:29393 - PubMed

References

    1. Nat Cell Biol. 2006 Nov;8(11):1223-34 - PubMed

References

    1. J Cell Mol Med. 2009 Sep;13(9A):2911-25 - PubMed

References

    1. J Cell Biol. 2006 Aug 14;174(4):593-604 - PubMed

References

    1. Int J Clin Exp Med. 2015 Oct 15;8(10):19466-70 - PubMed

References

    1. Cell Tissue Res. 2003 Oct;314(1):15-23 - PubMed

References

    1. Am J Pathol. 2011 Aug;179(2):942-53 - PubMed

References

    1. J Neurosci. 2012 Nov 7;32(45):15715-27 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2011 May 17;108(20):8287-92 - PubMed

References

    1. Acta Neuropathol. 2011 Jul;122(1):1-9 - PubMed

References

    1. Arch Ophthalmol. 1995 Dec;113(12):1538-44 - PubMed

References

    1. Nat Immunol. 2014 Mar;15(3):215-7 - PubMed

References

    1. Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):e107-15 - PubMed

References

    1. Front Cell Neurosci. 2014 Nov 03;8:362 - PubMed

References

    1. Pharmacol Res. 2016 Jan;103:253-69 - PubMed

References

    1. Curr Eye Res. 2010 Dec;35(12):1045-56 - PubMed

References

    1. Cancer Res. 2017 Aug 15;77(16):4434-4447 - PubMed

References

    1. Nat Cell Biol. 2014 Apr;16(4):309-21 - PubMed

References

    1. Nat Commun. 2017 Sep 29;8(1):748 - PubMed

References

    1. Diabetes Obes Metab. 2015 Mar;17(3):219-30 - PubMed

References

    1. J Diabetes Res. 2015;2015:582060 - PubMed

References

    1. Am J Pathol. 2009 Dec;175(6):2676-85 - PubMed

References

    1. Exp Diabetes Res. 2012;2012:896362 - PubMed

References

    1. N Engl J Med. 2012 Mar 29;366(13):1227-39 - PubMed

References

    1. J Diabetes Sci Technol. 2009 Jul 01;3(4):924-30 - PubMed

References

    1. Nat Cell Biol. 2008 Aug;10(8):923-34 - PubMed

References

    1. FASEB J. 2016 Apr;30(4):1670-82 - PubMed

References

    1. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):101-11 - PubMed

References

    1. J Clin Endocrinol Metab. 2012 Dec;97(12):E2271-6 - PubMed

References

    1. J Ophthalmol. 2015;2015:605946 - PubMed

References

    1. EMBO J. 2008 Apr 9;27(7):993-1004 - PubMed

References

    1. Diabetologia. 2011 Sep;54(9):2409-16 - PubMed

References

    1. Diabetes. 2007 Sep;56(9):2380-7 - PubMed

References

    1. Blood. 2011 Jun 30;117(26):6999-7006 - PubMed

References

    1. Diabetes. 2010 Oct;59(10):2637-45 - PubMed

References

    1. Blood. 2013 Oct 17;122(16):2911-9 - PubMed

References

    1. Eur J Ophthalmol. 2011;21 Suppl 6:S3-9 - PubMed

References

    1. Arch Ophthalmol. 2008 Feb;126(2):227-32 - PubMed

References

    1. Invest Ophthalmol Vis Sci. 2011 Sep 29;52(10):7556-64 - PubMed

References

    1. Diabetes. 2015 Oct;64(10):3554-63 - PubMed

References

    1. Arch Ophthalmol. 1968 Sep;80(3):332-7 - PubMed

References

    1. Dis Model Mech. 2012 Jul;5(4):444-56 - PubMed

References

    1. N Engl J Med. 1994 Dec 1;331(22):1480-7 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback